DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • India
  • /
  • Healthcare
Author Program NEWCreate Narrative
543220 logo

Max Healthcare Institute Limited Stock Price

BSE:543220 Community·₹1.0t Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 15 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

543220 Share Price Performance

₹0
-1180.75 (-100.00%)
​
₹1,172.62
Fair Value
₹0
-1180.75 (-100.00%)
​
Price ₹0
Mon, 10 Aug 26
Fair Value₹1,172.62
Share Pricen/a

543220 Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value ₹1.17k 11.4% undervalued intrinsic discount

Expanding Premium Healthcare In India Will Meet Rising Demand

0users have liked this narrative
0users have commented on this narrative
9users have followed this narrative
AN
AnalystLowTarget
AnalystLowTarget's
Fair Value
·
Fair Value ₹940.48 10.5% overvalued intrinsic discount

Northern India Risks And Rising Capex Will Burden Future Operations

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
AnalystHighTarget
AnalystHighTarget's
Fair Value
·
Fair Value ₹1.41k 26.1% undervalued intrinsic discount

Rising Disposable Incomes And Aging Populations Will Drive Healthcare Demand

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
543220 logo
Max Healthcare Institute
26.1% undervalued intrinsic discount

Rising Disposable Incomes And Aging Populations Will Drive Healthcare Demand

View narrative
AN
AnalystHighTarget
AnalystHighTarget
Updated 24 Aug
Read Narrative
543220 logo
Max Healthcare Institute
11.4% undervalued intrinsic discount

Expanding Premium Healthcare In India Will Meet Rising Demand

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Updated 10 Aug
Read Narrative
543220 logo
Max Healthcare Institute
10.5% overvalued intrinsic discount

Northern India Risks And Rising Capex Will Burden Future Operations

View narrative
AN
AnalystLowTarget
AnalystLowTarget
Updated 27 Jul
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

AN
AnalystHighTarget
543220 logo

543220: Upcoming Board Results Will Support Stronger Lucknow Expansion Upside

Fair Value: ₹1.41k 26.1% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystConsensusTarget
543220 logo

543220: Lucknow Hospital Expansion And Dividend Plans Will Shape Steady Outlook

Fair Value: ₹1.17k 11.4% undervalued intrinsic discount
9 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystLowTarget
543220 logo

543220: Lucknow Bed Expansion Will Sustain Pressure On Rich P E

Fair Value: ₹940.48 10.5% overvalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

High growth potential with solid track record.

0 Risks
2 Rewards
View Full Analysis

Max Healthcare Institute Limited Key Details

₹87.1b

Revenue

₹32.7b

Cost of Revenue

₹54.5b

Gross Profit

₹39.9b

Other Expenses

₹14.6b

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
14.97
62.52%
16.72%
32.4%
View Full Analysis

About 543220

Founded
2001
Employees
15114
CEO
Abhay Soi
WebsiteView website
www.maxhealthcare.in

Max Healthcare Institute Limited provides medical and healthcare services in India. It offers services in various specialties, including cardiac sciences, orthopedics, oncology, renal sciences, neurosciences, minimal access and general surgery, pulmonology, obstetrics, bone marrow transplant, bariatric/weight loss surgery, gynecology, minimal access/laparoscopic surgery, eye care/ophthalmology, robotic surgery, paediatrics, nephrology, liver and biliary sciences, gastroenterology and GI surgery, internal medicine, organ transplants, and plastic and reconstructive surgery. The company also provides Max@Home, a platform that offers health and wellness services at home; and Max Lab, which provides diagnostic testing services to patients. In addition, it offers organ and tissue donation, preventive health checks, ambulance and immigration, air ambulance, and insurance and TPA services. The company provides healthcare services through a network of primary care clinics, multi-specialty hospitals/medical centres, and super-specialty hospital facilities. Max Healthcare Institute Limited was incorporated in 2001 and is based in Gurugram, India.

Recent 543220 News & Updates

User avatar
Narrative Update • Aug 24

543220: Upcoming Board Results Will Support Stronger Lucknow Expansion Upside

Analysts have adjusted their price target for Max Healthcare Institute from ₹1,370 to about ₹1,406. This reflects updated assumptions around fair value, discount rate, revenue growth, profit margin and future P/E multiples.
User avatar
Narrative Update • Aug 10

543220: Lucknow Hospital Expansion And Dividend Plans Will Shape Steady Outlook

Analysts have trimmed their price target for Max Healthcare Institute to about ₹1,173 from roughly ₹1,201. This reflects slightly revised assumptions on fair value, revenue growth, profit margins, the discount rate and future P/E multiples.

Recent updates

No updates

Max Healthcare Institute Limited Competitors

View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide